ArticleEuropean radiology2026
The mismatch between PRISMA and AMSTAR-2: Does adherence to one standard set authors up to fail another?
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement and AMSTAR-2 are widely used to support the reporting and methodological appraisal of systematic reviews, respectively. Although conceptually complementary, the frameworks are not fully aligned. Consequently, reviews that adhere closely to PRISMA 2020 may receive low AMSTAR-2 confidence ratings. Five recent PRISMA-compliant meta-analyses published in European Radiology illustrate this disconnect: all were rated as having "low" AMSTAR-2 confidence as they failed to provide a detailed list and justification of excluded studies and to report the funding sources of included studies, requirements emphasised by AMSTAR-2 but not formulated as equivalent standalone requirements in PRISMA 2020. Similar patterns have been reported in other clinical fields, suggesting structural misalignment rather than uniformly poor methodological quality. The discrepancy is amplified by AMSTAR-2's designation of critical domains, whereby a single unmet critical item can substantially lower the overall confidence rating, as well as by ambiguity in interpreting certain criteria. Although AMSTAR-2 was intended to support contextual methodological appraisal rather than simple scoring, it is frequently applied as a rigid checklist. Better alignment could include more graduated AMSTAR-2 judgements, clearer appraisal guidance, and incorporation into PRISMA of selected methodological elements emphasised by AMSTAR-2. Ultimately, journals, reviewers, and authors should distinguish reporting completeness from methodological quality and apply both frameworks thoughtfully, transparently, and with appropriate contextual judgement. KEY POINTS: Question Why can PRISMA 2020-compliant systematic reviews receive low AMSTAR-2 confidence ratings? Findings There is structural misalignment between AMSTAR-2 and PRISMA 2020 requirements, and failure to meet a single critical item in AMSTAR-2 can substantially lower the overall rating. Clinical relevance Better alignment between the frameworks and more context-sensitive appraisal are needed to avoid misleading assessments of systematic reviews.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.